Understanding Biologic Drug Access
A practical guide to prior authorization, step therapy, specialty pharmacy, and appeals
A note before reading:
Insurance coverage rules for biologics vary by plan, employer, state, and year. What follows explains how the access system usually works; it does not describe the rules for any specific plan. Use this guide to orient yourself, then check the details with your insurer, your doctor’s office, and the drug manufacturer’s patient assistance program.
Biologics are increasingly central to treatment across rheumatologic and autoimmune conditions, and newly relevant to Sjogren’s patients following the drug development pipeline. That means that more patients will be navigating new insurance and access steps they may not have needed before. This guide aims to orient people who are new to the process.
What is a biologic?
Most medications you’ve taken, whether over-the-counter or by prescription, are small-molecule drugs. They’re synthesized from chemicals, stable at room temperature, often available as inexpensive generics after patent expiration.
Biologics used in autoimmune disease are almost always monoclonal antibodies. These are proteins engineered to attach to a single molecular target. Older immunosuppressants tend to dampen immune activity broadly; a biologic blocks a specific inflammatory signal. That precision is what makes them a meaningful option for patients who haven’t responded to conventional treatment. Yet that’s also what makes them expensive to manufacture. Each antibody has to be grown in living cells and purified to exacting standards.
That manufacturing complexity shows up in the price. In the United States, list prices for biologics commonly fall between $20,000 and $60,000 per year before insurance and discounts, and some exceed $100,000. Almost nobody pays list price. Insurance negotiation and manufacturer assistance programs both reduce costs significantly. Still, list price sets the starting point for those adjustments and affects every access issue below.
Why aren’t there generics?
When a small-molecule drug’s patent expires, other manufacturers can make chemically identical copies. Biologics can’t have exact generics because they’re grown in living cells, not synthesized from a formula. No two manufacturers can produce a molecule that’s literally identical. Instead, companies make biosimilars: products highly similar to the original, with no clinically meaningful differences shown through testing.
Proving biosimilarity costs hundreds of millions of dollars and takes years. Biologic makers also file additional patents on formulations, delivery devices, and manufacturing methods, which delays competition further. The result is weaker generic-like competition and list prices that stay high longer.
Prior authorization: how it works
Insurers almost always require prior authorization before they will cover a biologic. The insurer typically asks for a documented diagnosis, evidence you tried required earlier treatments (see step therapy), notes on disease severity, and confirmation that your prescriber and the infusion facility (when relevant) are in-network.
Your doctor’s office sends the request. The insurer can approve it (usually for 6 to 12 months), deny it with reasons, or ask for more documentation. Standard decisions can take up to 14 calendar days; urgent requests are often handled in 24 to 72 hours.
Common denial reasons:
step therapy requirements haven’t been satisfied
insufficient documentation of disease severity
the specific drug is not covered under your formulary
off-label use without adequate supporting documentation (particularly relevant for Sjogren's patients, where biologics are used off-label)
A denial is not the final answer. The denial letter must say why the request was denied and cite the criteria used. That information is what you need to build an appeal.
Step therapy
Step therapy requires you to try and fail one or more treatments before your insurer will cover the drug your physician prescribed. For biologics, this typically means documenting failure on a conventional DMARD (like methotrexate or hydroxychloroquine) and sometimes a first-line biologic before a newer or more expensive treatment is approved.
Insurers define “failure” differently. Most accept inadequate benefit or documented intolerance (side effects that forced you to stop), typically after a trial period of about three months. Learn the exact wording your insurer uses for failure before you file an appeal.
State step therapy protections
As of early 2026, thirty-seven states had passed some form of step therapy patient protection law, though this number changes as legislation advances. The National Psoriasis Foundation maintains a current state-by-state map (linked below).
Protections often include exceptions when you already failed the required drug under a prior insurance plan, when the required drug is contraindicated, or when your physician believes it will not be effective for you. Many laws also require insurers to respond to exception requests within specific timeframes.
One important caveat: employer-funded insurance plans are governed by the federal law ERISA and may not qualify for state protections. If you get insurance through your employer, ask your HR department what type of plan you have.
Specialty pharmacy
Most biologics are dispensed through specialty pharmacies. These pharmacies handle cold-chain storage, follow up on prior authorizations, enroll patients in manufacturer assistance programs, provide injection training, and coordinate refills in ways that regular retail pharmacies do not.
Insurers often use preferred specialty pharmacy networks, so you may be required to use a specific pharmacy. Ask which pharmacies are in-network before your prescription is sent.
For infused biologics, where you receive the infusion affects coverage. Infusions at a clinic usually go through your medical benefit; home infusions usually fall under your pharmacy benefit. Those benefits involve different cost-sharing rules and different compatibility with manufacturer assistance programs, so ask your insurer which benefit will apply to your treatment.
Reducing your out-of-pocket cost
Copay assistance programs: Many manufacturers offer copay assistance for commercially insured patients, sometimes covering part or all of your copay or coinsurance, and occasionally capping annual out-of-pocket costs. You typically enroll through the manufacturer’s website or with your doctor’s office.
Patient assistance programs (PAPs): For uninsured, underinsured, or Medicare/Medicaid patients, most manufacturers also offer programs that provide the drug at no cost to qualifying patients based on income. Eligibility thresholds are often more generous than people expect. Some programs extend to household incomes well above $100,000, depending on family size. NeedyMeds and the Arthritis Foundation maintain current PAP databases.
If insurance says no
A denial is the beginning of a process, not the end. Appeals work best when they target the specific denial reason and provide complete documentation.
Peer-to-peer review: Ask your doctor’s office to request this before filing a formal written appeal. It’s a direct call between your doctor and the insurer’s medical reviewer, and it can resolve documentation-based denials faster than any other route. Some insurers close this option once a formal written appeal is filed. Request it immediately after a denial to preserve your options.
Internal appeal: A formal written request reviewed by different staff than those who issued the denial. Insurers must respond within 30 days for standard requests, 72 hours for urgent ones.
External review: If your internal appeal is denied, you have the right to an independent review by an organization not affiliated with your insurer, and their decision is binding. This is often the most effective route when a denial appears to contradict medical evidence.
The most effective appeals respond point-by-point to the denial reason, not with a general argument that the drug is necessary. A physician letter addressing the specific criteria cited in the denial letter is the single most valuable element. If the denial cites step therapy requirements you believe you’ve already satisfied, document your prior treatment attempts and outcomes.
The Patient Advocate Foundation (patientadvocate.org) offers case management for insurance coverage disputes. The Arthritis Foundation and Lupus Foundation of America also provide insurance navigation support.
Other barriers
Insurance coverage is the most discussed access barrier to biologics, but not the only one.
Location: For infused biologics, the distance to an in-network infusion center can be a serious obstacle in rural areas. Travel time and time off work matter when you are managing an active condition.
Race and ethnic disparities: Research shows that Black, Hispanic, and Asian patients with autoimmune and other immune-mediated conditions are less likely to receive biologic treatment than white patients with similar disease severity. A systematic review in the American Journal of Managed Care identified race and ethnicity as among the most frequently cited factors associated with disparities in biologic access, alongside insurance type, high out-of-pocket costs, and prior authorization requirements. These gaps reflect systemic inequities in specialty care access, not differences in disease biology.
Off-label complexity: When a biologic is used off-label, insurers may apply stricter review. Ask your doctor whether their clinical rationale is documented in terms the insurer will use to authorize treatment.
Administrative burden: Managing prior authorization, specialty pharmacy coordination, appeal deadlines, and renewal timelines is mentally taxing under any circumstances. For patients in a flare, managing fatigue, or working demanding jobs, it can be a lot.
Practical steps
Learn what step therapy your insurer requires and whether your treatment history already meets it.
If a prior authorization is submitted, ask your doctor’s office for a copy of what they sent.
If you receive a denial, ask the office to request a peer-to-peer review before filing a formal written appeal, remembering some insurers limit that option after a formal appeal.
Consider a patient advocate when the process becomes confusing, the denial reason is unclear, or coordinating documentation is overwhelming. Organizations like the Patient Advocate Foundation offer free case management for patients with a serious health condition. You can involve an advocate at any stage, including before you file a formal appeal.
For more information:
Understanding biologics
Step therapy
Patient assistance programs
Appeals and patient rights
Navigation and advocacy support
Disparities in biologic access
Corrections and clarifications always welcome: kelly@theconnectivethread.com.
The Connective Thread is written by a patient, not a clinician. Nothing here is medical advice.